consequence of PDT,” she revealed. Overexpression of VEGF seems to contribute to the growth and metastasis of cancers. Therefore, the VEGF pathway represents a prime area for therapeutic intervention, because drugs such as bevacizumab (Avastin) may inhibit
Search Results
Using Cellular Mechanisms to Develop Effective Combinations of Photodynamic Therapy and Targeted Therapies
Tayyaba Hasan
Updates to the Management of Kidney Cancer
Eric Jonasch
bevacizumab was compared with sunitinib in 950 patients in the IMmotion 151 trial. 9 Patients were stratified according to MSKCC risk score, liver metastases, and PD-L1 status. Of these, 40% were positive for PD-L1. Median PFS was 11.2 months for the
Off-Label Use of Oncology Drugs: Too Much, Too Little, or Just Right?
Harold J. Burstein
constitute what most observers would consider appropriate use. The 10 drugs in this analysis (albumin-bound paclitaxel, azacytidine, bevacizumab, bortezomib, cetuximab, docetaxel, gemcitabine, pemetrexed, rituximab, and trastuzumab) are products well
In Defense of Hepatic Arterial Infusion for Hepatic Metastases of Colorectal Cancer
Nancy Kemeny
. 11. Giantonio BJ Catalano PJ Meropol NJ . Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200
QIM22-198: Optimizing a Systemic Platform to Standardize Oncologic Biosimilars Utilization at Cedars-Sinai Medical Center (CSMC)
Suwicha Limvorasak, Hilary Teaford, Crystal Leung Dobbs, Kyung Kim, Marcio A. Diniz, Andre Rogatko, Edwin M. Posadas, Kevin S. Scher, Vipul Patel, Bruce Vinson, Leanne Sakamoto, Rita Shane, Robert A. Figlin, and Karen L. Reckamp
substitution within the electronic order set. For this interim report, we identified adult cancer patients who initiated treatment with bevacizumab, rituximab or trastuzumab between January to October 2021 through electronic health record. Conversion rate was
QIM22-203: Randomized Trial of Implementing a Clinical Decision Support Tool for Automatic Selection of Payor-Mandated Biosimilar at Time of Prescribing
Shayna Simon, Lindsey Skelton, Sherry F. Parker, Rebecca Brian, Waddah Arafat, and Muhammad Shaalan Beg
tool is being validated for two additional oncology reference products (bevacizumab, trastuzumab). EMR based tools can help manage the complexity of ordering biosimilars in the current healthcare system.
QIM24-183: Novel Therapies in the Oncology Care Model: A Profile in Review.
Puneeth Indurlal and Lalan S. Wilfong
similar agents (rituximab-hyaluronidase, bortezomib, bendamustine), biosimilars and generics did not receive the status. Legacy drugs (melphalan, bevacizumab, rituximab, etc.), and non-chemotherapy drugs (denosumab) also received novel therapy status for
QIM20-124: Retrospective Evaluation of VEGF Inhibitor-Associated Hypertension at a Community Cancer Center
Jasmin Eugene, Carli Nesheiwat, and Scott Overmier
retrospective, single-center, chart review assessed patients’ blood pressure measurements who received bevacizumab, ramucirumab, sorafenib, regorafenib, sunitinib, or pazopanib. Patients were excluded if they were less than 18, received VEGF inhibitors for non
NCCN Guidelines® Updates: Kidney Cancer
Certain Circumstances: ∘ “Bevacizumab .... and renal cell cancer carcinoma (HLRCC)- associated RCC ” was revised.
BPI20-012: Relative Risk of Various Endocrinopathies Associated With the Use of Immune Checkpoint Inhibitors in the First-Line Treatment of Advanced Renal Cell Carcinoma: a Systematic Review and Meta-Analysis
Nusrat Jahan, Francis Mogollon-Duffo, Miguel Quirch, Somedeb Ball, Fred Hardwicke, Lukman Tijani, and Shabnam Rehman
. For hypophysitis and diabetes, CheckMate 214 and KEYNOTE-426 including 1936 patients were analyzed. ICI regimens used in the study arms are — CheckMate 214: nivolumab + ipilimumab; IMmotion151: atezolizumab + bevacizumab; JAVELIN Renal 101: axitinib
